A Multicenter Analysis of Immune Checkpoint Inhibitors As Adjuvant Therapy Following Treatment of Isolated Brain Metastasis

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2020 Nov 23

PMID 33225544

Citations 2

Authors

J Randall Patrinely Jr

Elisa Funck-Brentano

Khang Nguyen

Suthee Rapisuwon

Joe-Elie Salem

Geoffrey T Gibney

Matteo Carlino

Douglas B Johnson

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this work was to characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy.

Materials And Methods: Patients from four medical centers were included if they presented with isolated brain metastases treated with local therapy and received adjuvant treatment with ICIs.

Results: Eleven patients with median size of largest brain metastasis of 3.9 cm, treated with surgical resection (n = 8) and/or stereotactic radiosurgery (SRS; n = 6), were included. Ipilimumab/nivolumab was the adjuvant ICI used in four patients, of whom one recurred (25%) and none died, compared with three of seven (43%) who recurred and two of seven (29%) who died following adjuvant treatment with ICI monotherapy. All recurrences were intracranial.

Conclusion: Patients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI therapy, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially.

Citing Articles

Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases.

Yoo K, Park D, Choi J, Marianayagam N, Lim M, Meola A Front Oncol. 2023; 13:1223599.

PMID: 37637032 PMC: 10456862. DOI: 10.3389/fonc.2023.1223599.

Brain metastasis: Recent treatment modalities and future-perspectives.

Katano A, Yamashita H Oncol Lett. 2022; 23(6):191.

PMID: 35527784 PMC: 9073579. DOI: 10.3892/ol.2022.13311.

References

Ahmed K, Abuodeh Y, Echevarria M, Arrington J, Stallworth D, Hogue C . Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016; 27(12):2288-2294. PMC: 8890451. DOI: 10.1093/annonc/mdw417. View

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

Weber J, Mandala M, Del Vecchio M, Gogas H, Arance A, Cowey C . Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017; 377(19):1824-1835. DOI: 10.1056/NEJMoa1709030. View

Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S . Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19):1789-1801. DOI: 10.1056/NEJMoa1802357. View

Zimmer L, Livingstone E, Hassel J, Fluck M, Eigentler T, Loquai C . Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 395(10236):1558-1568. DOI: 10.1016/S0140-6736(20)30417-7. View

Long G, Atkinson V, Lo S, Sandhu S, Guminski A, Brown M . Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018; 19(5):672-681. DOI: 10.1016/S1470-2045(18)30139-6. View

Pires da Silva I, Glitza I, Haydu L, Johnpulle R, Banks P, Grass G . Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell Melanoma Res. 2019; 32(4):553-563. PMC: 8258671. DOI: 10.1111/pcmr.12775. View

Tawbi H, Forsyth P, Algazi A, Hamid O, Hodi F, Moschos S . Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018; 379(8):722-730. PMC: 8011001. DOI: 10.1056/NEJMoa1805453. View

Kluger H, Chiang V, Mahajan A, Zito C, Sznol M, Tran T . Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. J Clin Oncol. 2018; 37(1):52-60. PMC: 6354772. DOI: 10.1200/JCO.18.00204. View

10.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View